Judith Trotman, MD

ROSEWOOD rapid readout: zanubrutinib plus obinutuzumab boosts durable responses and progression-free survival in relapsed follicular lymphoma, with manageable long-term safety.

Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.